
SNYR Stock Forecast & Price Target
SNYR Analyst Ratings
Bulls say
Synergy CHC is currently undervalued with an attractive NPV-based price target of $3.75, presenting significant upside potential. The company's strong balance sheet, with $0 million in cash and $28 million in debt, compared to $3 million in cash and $27 million in debt at the end of December, provides stability and room for growth through new RTD products and international expansion. However, risks to the attainment of the price target include factors such as liquidity risks, competition, and changing consumer trends.
Bears say
Synergy CHC is facing challenges including weak Q1 results and the termination of a distribution deal. However, the company's strong FOCUSfactor brand and growth in the brain health supplements industry may present future opportunities. The recent weakness in share price and the company's solid long-term financial performance make the stock undervalued. Near-term catalysts such as new RTD products and international growth could positively impact the stock in 2026.
This aggregate rating is based on analysts' research of Synergy CHC Corp and is not a guaranteed prediction by Public.com or investment advice.
SNYR Analyst Forecast & Price Prediction
Start investing in SNYR
Order type
Buy in
Order amount
Est. shares
0 shares